Kazia Therapeutics (KZIA) Stock Forecast & Price Target

Kazia Therapeutics is well-positioned with their primary program, Paxalisib, and other candidates in their portfolio to address multiple cancer indications and potentially generate significant revenue. However, there are risks involved in the completion of clinical trials and obtaining marketing approval. The company is projected to peak sales opportunities of $580M for Paxalisib and $500M for other candidates. Investors should monitor updates on the drug, expected in December 2026, and first patient enrollment, expected by the end of 2026.

Kazia Therapeutics is still in the early stages of its drug development program, and while its primary program, Paxalisib, has shown positive early efficacy, the sample size is small and cross-trial comparisons will be needed before it can be considered comparable to established benchmarks. The company has yet to produce a larger dataset or head-to-head evidence against other PI3K-pathway agents, leaving its potential biology-modulating and immunomodulatory profile unproven. Expansion of the Arm B target enrollment could provide more meaningful data, but with a projected peak sales opportunity of only ~$580M, the company may not be able to generate significant revenues.